KANEDA Hiroyasu 金田裕靖

… Alternative Names

金田裕靖カネダヒロヤス

Less

Researcher Number	50351599
Other IDs
Affiliation (Current)	2023: 大阪公立大学, 大学院医学研究科, 准教授
Affiliation (based on the past Project Information) *help	2012 – 2017: 近畿大学, 医学部, 講師
Review Section/Research Field	Principal Investigator Tumor therapeutics / Tumor diagnostics / Clinical oncology
Keywords	Principal Investigator Digital PCR / 耐性克服 / EGFRチロシンキナーゼ阻害剤耐性 / EGFR遺伝子変異陽性肺がん / 血漿DNA / 分子標的治療 / バイオマーカー / ＥＭＴ / EMT / 抗がん剤耐性 / 化学療法

Research Projects
(2 results)
Research Products
(25 results)

Acquired resistance mechanism to EGFR-TKI using circulating cell-free tumor DNAPrincipal Investigator
- Principal Investigator
  
  KANEDA Hiroyasu
- Project Period (FY)
  2015 – 2017
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Tumor diagnostics
  Tumor therapeutics
- Research Institution
  Kindai University
To provide a biomarker for predicting the therapeutic effect of chemotherapy to lung cancer harboring EGFR mutation.Principal Investigator
- Principal Investigator
  
  KANEDA Hiroyasu
- Project Period (FY)
  2012 – 2014
- Research Category
  
  Grant-in-Aid for Young Scientists (B)
- Research Field
  
  Clinical oncology
- Research Institution
  Kinki University

All 2014 2013 2012 Other

All Journal Article Presentation

[Journal Article] Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.2014
- Author(s)
  Okamoto I, Sakai K, Morita S, Yoshioka H, Kaneda H, Takeda K, Hirashima T, Kogure Y, Kimura T, Takahashi T, Atagi S, Seto T, Sawa T, Yamamoto M, Satouchi M, Okuno M, Nagase S, Takayama K, Tomii K, Maeda T, Oizumi S, Fujii S, Akashi Y, Nishino K, Ebi N, Nakagawa K, Nakanishi Y, Nishio K.
- Journal Title
  
  Oncotarget
  
  Volume: 5(8) Pages: 2293-2304
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).2014
- Author(s)
  Horinouchi H, Yamamoto N, Nokihara H, Horai T, Nishio M, Ohyanagi F, Horiike A, Nakagawa K, Terashima M, Okabe T, Kaneda H, McKee MD, Carlson DM, Xiong H, Tamura T.
- Journal Title
  
  Cancer Chemother Pharmacol
  
  Volume: 74(1) Issue: 1 Pages: 37-43
- DOI
  10.1007/s00280-014-2478-9
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.2014
- Author(s)
  Kidera Y, Kawakami H, Sakiyama T, Okamoto K, Tanaka K, Takeda M, Kaneda H, Nishina S, Tsurutani J, Fujiwara K, Nomura M, Yamazoe Y, Chiba Y, Nishida S, Tamura T, Nakagawa K.
- Journal Title
  
  PLoS One
  
  Volume: 9(7) Issue: 7 Pages: e101902-e101902
- DOI
  10.1371/journal.pone.0101902
- Peer Reviewed / Open Access
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer.2012
- Author(s)
  Tanaka K, Arao T, Tamura D, Aomatsu K, Furuta K, Matsumoto K, Kaneda H, Kudo K, Fujita Y, Kimura H, Yanagihara K, Yamada Y, Okamoto I, Nakagawa K, Nishio K.
- Journal Title
  
  PLoS One
  
  Volume: 7(1)
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] Pharmacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis.2012
- Author(s)
  Kaneda H, Okamoto I, Nakagawa K.
- Journal Title
  
  J Thorac Oncol
  
  Volume: 7(3) Pages: 621-622
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] Reversible posterior leukoencephalopathy syndrome and trastuzumab.2012
- Author(s)
  Kaneda H, Okamoto I, Satoh T, Nakagawa K.
- Journal Title
  
  Invest New Drugs
  
  Volume: 30(4) Pages: 1766-1767
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma.2012
- Author(s)
  Kaneda H, Okamoto I, Sakai K, Tanizaki J, Takeda M, Nishio K, Nakagawa K.
- Journal Title
  
  Acta Oncol
  
  Volume: 51(7) Pages: 942-944
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.2012
- Author(s)
  Tanizaki J, Okamoto I, Okabe T, Sakai K, Tanaka K, Hayashi H, Kaneda H, Takezawa K, Kuwata K, Yamaguchi H, Hatashita E, Nishio K, Nakagawa K.
- Journal Title
  
  Clin Cancer Res
  
  Volume: 18(22) Pages: 6219-6226
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.2012
- Author(s)
  Sakai K, Okamoto I, Takezawa K, Hirashima T, Kaneda H, Takeda M, Matsumoto K, Kimura H, Fujita Y, Nakagawa K, Arao T, Nishio K.
- Journal Title
  
  J Thorac Oncol
  
  Volume: 7(5) Pages: 913-918
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.2012
- Author(s)
  Fujita Y, Islam R, Sakai K, Kaneda H, Kudo K, Tamura D, Aomatsu K, Nagai T, Kimura H, Matsumoto K, de Velasco MA, Arao T, Okawara T, Nishio K.
- Journal Title
  
  Invest New Drugs
  
  Volume: 30(5) Pages: 1878-1886
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells.2012
- Author(s)
  Furuta K, Arao T, Sakai K, Kimura H, Nagai T, Tamura D, Aomatsu K, Kudo K, Kaneda H, Fujita Y, Matsumoto K, Yamada Y, Yanagihara K, Sekijima M, Nishio K.
- Journal Title
  
  Cancer Sci
  
  Volume: 103(2) Pages: 221-227
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Journal Article] Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.2012
- Author(s)
  Matsuoka H, Makimura C, Koyama A, Otsuka M, Okamoto W, Fujisaka Y, Kaneda H, Tsurutani J, Nakagawa K.
- Journal Title
  
  Anticancer Res
  
  Volume: 32(5) Pages: 1805-1809
- Peer Reviewed
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Phase I study of Patritumab (U3-1287) in combination with Erlotinib in NSCLC patients.2013
- Author(s)
  金田裕靖・中川和彦・工藤慶太・西尾誠人・村上晴泰・山本信之・堀之内秀仁・田村友秀
- Organizer
  第54回日本肺癌学会総会
- Place of Presentation
  ホテルニューオータニ（東京都千代田区）
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Phase I study of ombrabulin , a vascular disrupting agent (VDA) in Japanese patients with advanced solid tumors.2012
- Author(s)
  Murakami H, Kurata T, Fujisaka Y, Hayashi H, Tanaka K, Kaneda H, Nakagawa K, Yokota T, Boku N, Yamamoto N.
- Organizer
  第71回日本癌学会学術総会
- Place of Presentation
  札幌市
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Antitumor action of the MET tyrosine kinase inhibitor crizotinib in gastric cancer positive for MET amplification.2012
- Author(s)
  Okamoto W, Okamoto I, Arao T, Sakai K, Okamoto K, Kawakami H, Kaneda H, Nishina S, Tsurutani J, Kurata T, Yanagihara K, Nishio K, and Nakagawa K.
- Organizer
  第71回日本癌学会学術総会
- Place of Presentation
  札幌市
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Overexpression of FOXQ1 is important factor in tumorigenecity and tumor growth.2012
- Author(s)
  Kaneda H, Arao T, Tanaka K, Matsumoto K, Kimura H, Nagai T, Sakai K, Fujita Y, de Velasco MA, Yamada Y, Tsurutani J, Okamoto I, Nakagawa K, and Nishio K.
- Organizer
  第10回日本臨床腫瘍学会学術集会
- Place of Presentation
  大阪市
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] A phase III study comparing amrubicin and cisplatin (AP) with irinotecan and cisplatin (IP) for the treatment of extended-stage small cell lung cancer (ED-SCLC): JCOG0509.2012
- Author(s)
  Kaneda H, Kotani Y, Satouchi M, Ando M, Yamamoto N, Ichinose Y, Ohe Y, Nishio M, Hida T, Takeda K, Kudoh S, Minato K, Shibata T, and Tamura T.
- Organizer
  第10回日本臨床腫瘍学会学術集会
- Place of Presentation
  大阪市
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Activin-A directly inhibits vascular endothelial cell growth via TGF-β dependent signal pathway.2012
- Author(s)
  Kaneda H, Arao T, Tanaka K, Matsumoto K, Kimura H, Nagai T, Fujita Y, de Velasco MA, Yamada Y, Okamoto I, Nakagawa K, and Nishio K.
- Organizer
  第10回日本臨床腫瘍学会学術集会
- Place of Presentation
  大阪市
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Chemotherapy with CPT-11 after gemcitabine failure in patients with advanced pancreatic cancer.
- Author(s)
  Kaneda H, Ueda S, Kawakami H, Tanizaki J, OkamotoK, Makimura C, Tanaka K, Matsuoka M, Okamoto W, Shimizu T, Fujisaka Y, Nishina S, Miyazaki M, Tsurutani J, Kurata T, Okamoto I, Nakagawa K.
- Organizer
  14th　World Congress of　Gastorientestinal　Cancer
- Place of Presentation
  スペイン　バルセロナ
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Clinical benefit of continued therapy with crizotinib beyond initial disease progression in advanced ALK-positive NSCLC.
- Author(s)
  Kaneda H
- Organizer
  第12回日本臨床腫瘍学会
- Place of Presentation
  福岡国際会議場
- Year and Date
  2014-07-17 – 2014-07-19
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Tumor genomic profiling of non-small cell lung cancers (NSCLC) from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin.
- Author(s)
  Kaneda H
- Organizer
  第12回日本臨床腫瘍学会
- Place of Presentation
  福岡国際会議場
- Year and Date
  2014-07-17 – 2014-07-19
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Update of Nintedanib (BIBF1120).
- Author(s)
  Kaneda H
- Organizer
  第55回日本肺癌学会学術集会
- Place of Presentation
  国立京都国際会館
- Year and Date
  2014-11-14 – 2014-11-16
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Second-line chemotherapy with S-1 after cisplatin and gemcitabine failure in patients with advance biliary tract cancer.
- Author(s)
  Ueda S, Kawakami H, Okamoto W,　Nishina S, Kudo T, Makimura C, Kiyota H, Tanaka K, Kaneda H, Fujisaka Y, Miyazaki M, Tsurutani J, Okamoto I, Kurata T, and Nakagawa K.
- Organizer
  14th　World Congress of　Gastorientestinal　Cancer
- Place of Presentation
  スペイン　バルセロナ
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Phase II study of erlotinib plus tivantinib in patients with EGFR mutation-positive NSCLC who failed in immediately previous EGFR-TKI therapy.
- Author(s)
  Kaneda H
- Organizer
  第55回日本肺癌学会学術集会
- Place of Presentation
  国立京都国際会館
- Year and Date
  2014-11-14 – 2014-11-16
- Data Source
  KAKENHI-PROJECT-24701037
[Presentation] Phase I study of CO-1686 (rociletinib), an irreversible, mutant-selective inhibitor of EGFR mutations, in Japanese patients with T790M-positive NSCLC.
- Author(s)
  Kaneda H
- Organizer
  第55回日本肺癌学会学術集会
- Place of Presentation
  国立京都国際会館
- Year and Date
  2014-11-14 – 2014-11-16
- Data Source
  KAKENHI-PROJECT-24701037

KANEDA Hiroyasu 金田 裕靖

金田 裕靖 カネダ ヒロヤス

Research Projects

Research Products

Acquired resistance mechanism to EGFR-TKI using circulating cell-free tumor DNAPrincipal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

To provide a biomarker for predicting the therapeutic effect of chemotherapy to lung cancer harboring EGFR mutation.Principal Investigator

Principal Investigator

Project Period (FY)

Research Category

Research Field

Research Institution

[Journal Article] Multiplex genomic profiling of non-small cell lung cancers from the LETS phase III trial of first-line S-1/carboplatin versus paclitaxel/carboplatin: results of a West Japan Oncology Group study.2014

Author(s)

Journal Title

Data Source

[Journal Article] A phase 1 study of linifanib in combination with carboplatin/paclitaxel as first-line treatment of Japanese patients with advanced or metastatic non-small cell lung cancer (NSCLC).2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] Risk factors for cisplatin-induced nephrotoxicity and potential of magnesium supplementation for renal protection.2014

Author(s)

Journal Title

DOI

Data Source

[Journal Article] SRPX2 is a novel chondroitin sulfate proteoglycan that is overexpressed in gastrointestinal cancer.2012

Author(s)

Journal Title

Data Source

[Journal Article] Pharmacokinetics of docetaxel in a patient with non-small cell lung cancer undergoing continuous ambulatory peritoneal dialysis.2012

Author(s)

Journal Title

Data Source

[Journal Article] Reversible posterior leukoencephalopathy syndrome and trastuzumab.2012

Author(s)

Journal Title

Data Source

[Journal Article] Marked response to both S-1 and pemetrexed in a patient with echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinoma.2012

Author(s)

Journal Title

Data Source

[Journal Article] Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.2012

Author(s)

Journal Title

Data Source

[Journal Article] A novel mass spectrometry-based assay for diagnosis of EML4-ALK-positive non-small cell lung cancer.2012

Author(s)

Journal Title

Data Source

[Journal Article] Aza-derivatives of resveratrol are potent macrophage migration inhibitory factor inhibitors.2012

Author(s)

Journal Title

Data Source

[Journal Article] Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells.2012

Author(s)

Journal Title

Data Source

[Journal Article] Pilot study of duloxetine for cancer patients with neuropathic pain non-responsive to pregabalin.2012

Author(s)

Journal Title

Data Source

[Presentation] Phase I study of Patritumab (U3-1287) in combination with Erlotinib in NSCLC patients.2013

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] Phase I study of ombrabulin , a vascular disrupting agent (VDA) in Japanese patients with advanced solid tumors.2012

Author(s)

Organizer

Place of Presentation

Data Source

[Presentation] Antitumor action of the MET tyrosine kinase inhibitor crizotinib in gastric cancer positive for MET amplification.2012

Author(s)

Organizer

Place of Presentation

KANEDA Hiroyasu 金田裕靖

金田裕靖カネダヒロヤス